

Hepatitis B virus

# Short interfering RNA JNJ-3989 combination therapy in chronic hepatitis B shows potent reduction of all viral markers but no correlate was identified for HBsAg reduction and baseline factors


**Edward Gane<sup>1</sup>, Stephen Locarnini<sup>2</sup>, Tien Huey Lim<sup>3</sup>, Simone I. Strasser<sup>4</sup>, William Sievert<sup>5</sup>, Wendy Cheng<sup>6,7</sup>, Alex J. Thompson<sup>8</sup>, Bruce D. Given<sup>9</sup>, Thomas Schlupe<sup>9</sup>, James Hamilton<sup>9</sup>, Michael Biermer<sup>10</sup>, Ronald Kalmeijer<sup>11</sup>, Maria Beumont<sup>11</sup>, Oliver Lenz<sup>10</sup>, Phillip De Ridder<sup>10</sup>, Gavin Cloherty<sup>12</sup>, Danny Ka-Ho Wong<sup>13</sup>, Christian Schwabe<sup>14</sup>, Kathy Jackson<sup>2</sup>, Carlo Ferrari<sup>15</sup>, Ching Lung Lai<sup>13</sup>, Robert G. Gish<sup>16</sup>, Man-Fung Yuen<sup>13</sup>**

*<sup>1</sup>University of Auckland, Auckland, New Zealand; <sup>2</sup>Victorian Infectious Diseases Reference Laboratory, Victoria, Australia; <sup>3</sup>Middlemore Hospital, Auckland, New Zealand; <sup>4</sup>Royal Prince Alfred Hospital, Sydney, Australia; <sup>5</sup>Monash Health and Monash University, Melbourne, Australia; <sup>6</sup>Royal Perth Hospital, Perth, Australia; <sup>7</sup>Linear Clinical Research, Perth, Australia; <sup>8</sup>St. Vincent's Hospital, Melbourne, Australia; <sup>9</sup>Arrowhead Pharmaceuticals, Pasadena, CA, USA; <sup>10</sup>Janssen Pharmaceuticals BV, Beerse, Belgium; <sup>11</sup>Janssen R&D, Titusville, NJ, USA; <sup>12</sup>Abbott Diagnostics, Abbott Park, IL, USA; <sup>13</sup>The University of Hong Kong, Hong Kong, China; <sup>14</sup>New Zealand Clinical Research; <sup>15</sup>University of Parma, Parma, Italy; <sup>16</sup>Hepatitis B Foundation, Doylestown, PA, USA*

# Disclosures for all authors

- **EG** has been an advisor and/or speaker for AbbVie, Aligos, Arbutus, Arrowhead, Assembly, Avalia, Clear B Therapeutics, Dicerna, DrugFarm, Enanta, Finch Therapeutics, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Novartis, Roche and Vir Bio.
- **SL** receives consulting fees from Roche Molecular, AusBio Ltd, Janssen, Abbvie and Clear-B, and contract research grants from Spring Bank Pharmaceuticals, Inc. and Clear-B.
- **SS** has received honoraria for advisory boards or speaker fees from Gilead, BMS, AbbVie, MSD, Bayer, Eisai, Ipsen, Pfizer and CSL.
- **AT** has served on advisory boards for Gilead, Abbvie, Merck, BMS, Bayer and Eisai, has received speaker fees from Gilead, Abbvie, Merck and BMS, and has received institutional research grants from Gilead, Abbvie and Merck.
- **BG, TS, and JH** are/were employees of Arrowhead and may be Arrowhead shareholders
- **MB, RK, MB, OL** and **FDR** are employees of Janssen Pharmaceuticals and may be Johnson & Johnson stockholders.
- **GC** is an Abbott employee and shareholder.
- **CS** has provided advice to Johnson & Johnson and Vir Biotechnology.
- **CF** is an advisory board member for Gilead, Roche, MSD, Abbvie, BMS and Vir, a consultant for Gilead, Arrowhead, Abbvie, Humabs (Ch), Abivax and Transgene, and receives research grants from Gilead, Roche, Abbvie and Bristol Myer Squibb.
- **CLL** discloses sponsored lectures for Gilead Sciences
- **RGG** had grants/research support from Gilead is/has been a consultant and/or advisor to Abbot, Abbvie, Access Biologicals, Antios, Arena, Arrowhead, Bayer AG, Bristol Myers Squibb, Dova, Dynavax, Eiger, Eisai, Enyo, eStudySite, Exelixis, Forty-Seven Inc, Genlantis, Gerson Lehrmann Group, Gilead Sciences, HepaTX, HepQuant, Intercept, Ionis, Janssen, Laboratory for Advanced Medicine, Lilly, Merck, Salix, Shionogi, Spring Bank, and Viking Therapeutics, hold positions on scientific or clinical advisory boards for: Abbott, AbbVie, Merck, Arrowhead, Bayer, Dova Pharmaceuticals, Eiger, Enyo, Hatch Biofund, HepQuant, Intercept, Jansen, Medimmune is an advisory consultant for Biocollections, Fujifilm/Wako, and Quest, is on the data safety monitoring board for Ionis, and Eiger, has consultant confidentiality agreements with: Abbot, Abbvie, Access Biologicals, ADMA Biologics, AEC Partners, Aligos Therapeutics, Arena Pharmaceuticals, Arrowhead, Arterys Inc, Alexion, Altimmune, Antios Therapeutics, AproTx, Bayer, Cirina, Consumer Health Products Assoc, DiaSorin Inc, Dova Pharmaceuticals, DRG Abacus, Dynavax, Echosens, Eiger, Enyo, Exelixis, Forty-Seven Inc, Fujifilm Wako Diagnostix, Gilead, HepQuant, HepaTx, IDLogiq, Intellia, Intercept, Inotek, Iqvia, Janssen/J&J, KannaLife, Laboratory for Advanced Medicine, Labyrinth Holdings, Lilly, MedImmune, Merck, New Enterprise Associates, Ogilvy CommonHealth, Organovo, Patient Connect, ProdigY Biotech, Prometheus Laboratories, Refuah Solutions, Regulus Therapeutics, Salix, Shionogi, Spring Bank, Trimaran, and Viking Therapeutic, has speaker contracts with Abbvie, Bayer, Bristol Myers Squibb, Dova Pharmaceuticals, Eisai, Gilead, Intercept, Salix, and Shionogi, is a minor stock shareholder in RiboSciences, has stock options in Eiger, AngioCrine, and HepQuant;
- **M-FY** serves as advisor/consultant for AbbVie, Arbutus Biopharma, Allovir International Bristol Myer Squibb, Clear B Therapeutics, Dicerna Pharmaceuticals, GlaxoSmithKline, Gilead Sciences, Janssen, Merck Sharp and Dohme, Roche and Springbank Pharmaceuticals, and receives grant/research support from Assembly Biosciences, Arrowhead Pharmaceuticals, Bristol Myer Squibb, Fujirebio Incorporation, Gilead Sciences, Merck Sharp and Dohme, Roche, Springbank Pharmaceuticals and Sysmex Corporation
- **T-HL, WS, WC, DK-HW** and **KJ** have no disclosures

# JNJ-3989: Mechanisms of action



- NAs inhibit viral replication but **do not prevent the production of HBsAg**
- In AROHBV1001, JNJ-3989 (**100–400 mg; 3 monthly injections**) in combination with NA (TDF or ETV) resulted in potent reduction of **HBsAg, HBeAg, HBV RNA and HBcrAg**, and was well tolerated in patients with CHB<sup>1</sup>
- The effects were sustained in 38% of patients until **Day 392** (336 days after last dose of JNJ-3989) with a mean (SE) HBsAg reduction of 1.96 (0.20) log<sub>10</sub> IU/mL in patients with “sustained” response\*<sup>1</sup>

1. Gane et al. EASL 2020. Oral presentation GS10. Sustained response was defined as a >1 log<sub>10</sub> IU/ml reduction in HBsAg from Day 0 through Day 392. cccDNA, covalently closed circular DNA; CHB, chronic hepatitis B; ETV, entecavir; HBeAg, hepatitis B e antigen; HBcrAg, hepatitis B core related antigen; HBsAg, hepatitis B surface antigen; HBV RNA, hepatitis B virus RNA; NA, nucleos(t)ide analogue; pgRNA, pregenomic RNA; SE, standard error; siRNA, short interfering RNA; TDF, tenofovir disoproxil fumarate

# AROHBV1001: Objectives of analyses through Day 168

**1**

**To assess the impact of baseline factors on HBsAg reduction during treatment with JNJ-3989 and NA**

**2**

**To compare the effect of JNJ-3989 and NA on HBsAg, HBeAg, HBcrAg and HBV RNA levels**

# AROHBV1001: Study design

Cohorts receiving JNJ-3989 (100–400mg; 3 x Q4W) + NA



## Study population:

1. CHB HBeAg-positive or -negative patients
2. NA-experienced or -naïve patients



## Dose administration:

- Injections (sc) of JNJ-3989 were given on Days 0, 28 and 56
- Oral QD treatment with TDF or ETV was started or continued on Day 0 and was administered throughout the study

# AROHBV1001: Baseline characteristics and demographics


Baseline patient characteristics of the JNJ-3989 3 x Q4W 100–400 mg cohort	
Baseline Characteristics	Number of patients (N=40)
Age, years; median (range)	45 (26–66)
Male, n (%)	29 (72.5)
Race, n (%)	
Asian	34 (85.0)
Caucasian	1 (2.5)
Other	5 (12.5)
NA-experienced, n (%)	32 (80.0)
HBeAg-positive, n (%)	14 (35.0)

Baseline levels of viral markers in the JNJ-3989 3 x Q4W 100–400 mg cohort*			
Viral maker	HBeAg Status	N	Mean (SE)
HBV DNA (log <sub>10</sub> IU/mL)	Negative	3	2.7 (0.5)
	Positive	8	6.7 (0.9)
HBV RNA (log <sub>10</sub> U/mL)	Negative	14	2.6 (0.2)
	Positive	14	6.3 (0.4)
HBcrAg (log <sub>10</sub> kU/mL)	Negative	11	0.9 (0.2)
	Positive	14	4.8 (0.3)
HBeAg (log <sub>10</sub> PEIU/mL)	Positive	14	1.7 (0.3)
HBsAg (log <sub>10</sub> IU/mL)	Negative	26	2.7 (0.1)
	Positive	14	3.9 (0.2)

\*Includes patients with viral marker concentrations >LLOQ.

HBeAg, hepatitis B e-antigen; HBcrAg, hepatitis B core related antigen; HBsAg, hepatitis B surface antigen; IU, international units; kU, kilo units; LLOQ, lower limit of quantification; NA, nucleos(t)ide analogue; PEIU, Paul Erlich Institute Units; Q4W, every 4 weeks; SE, standard error

# AROHBV1001: Effect of JNJ-3989 and NA treatment on reduction in HBsAg




- Mean (range) HBsAg reduction from baseline at nadir was 1.93 (0.73, 3.84)  $\log_{10}$  IU/mL

- 39/40 patients (98%) achieved >1  $\log_{10}$  IU/mL reduction at the nadir

Treatment with JNJ-3989 and NA resulted in pronounced HBsAg reductions

# AROHBV1001: Effect of JNJ-3989 and NA treatment on reduction in HBsAg according to baseline characteristics




Maximum HBsAg reduction from baseline n/N (%)	<2 log <sub>10</sub> IU/mL	≥2 log <sub>10</sub> IU/mL
<b>Overall</b>	28/40 (70)	12/40 (30)
<b>HBeAg<sup>+</sup></b>	6/14 (43)	8/14 (57)
<b>HBeAg<sup>-</sup></b>	22/26 (85)	4/26 (15)
<b>Female</b>	4/11 (36)	7/11 (64)
<b>Male</b>	24/29 (83)	5/29 (17)
<b>≤40 years old</b>	6/15 (40)	9/15 (60)
<b>&gt;40 years old</b>	22/25 (88)	3/25 (12)

Reductions in HBsAg were **more pronounced in HBeAg-positive patients compared with HBeAg-negative patients**




# AROHBV1001: Effect of JNJ-3989 and NA treatment on reduction in HBsAg according to treatment history



Treatment history was not associated with reductions in HBsAg

# AROHBV1001: Effect of JNJ-3989 and NA treatment on reduction in HBsAg according to baseline viral markers


Relationship between baseline viral markers and maximum reduction in HBsAg from baseline



Reduction in HBsAg was not associated with baseline HBsAg levels  
Larger reductions in HBsAg were associated with higher levels of HBV RNA, HBeAg and HBcrAg at baseline

# AROHBV1001: Effect of JNJ-3989 and NA treatment on reduction of all viral markers

Mean change of viral markers, comparing HBsAg with HBeAg, HBcrAg and HBV RNA from Day 0 to Day 168 (N=40)\*




**Reductions in HBsAg and HBV RNA were generally more pronounced compared with HBeAg and HBcrAg**

\*Only patients with baseline levels of HBeAg, HBcrAg and HBV RNA levels >1 log<sub>10</sub> IU/mL above LLOQ were included, respectively  
 HBcrAg, hepatitis B core related antigen; HBeAg, hepatitis B e-antigen; HBsAg, hepatitis B surface antigen; HBV RNA, hepatitis B virus RNA; IU, international unit; LLOQ, lower limit of quantification; NA, nucleos(t)ide analogue; PEIU, Paul Erlich Institute Units; SE, standard error

# AROHBV1001: Effect of JNJ-3989 and NA treatment on reduction of viral markers for individual patients (1/2)

Correlation between maximum HBsAg decline and HBeAg, HBcrAg and HBV RNA from Day 0 for individual patients\*




\*Only patients with baseline levels of HBeAg, HBcrAg and HBV RNA levels >1 log<sub>10</sub> above LLOQ were included

HBcrAg, hepatitis B core related antigen; HBeAg, hepatitis B e-antigen; HBsAg, hepatitis B surface antigen; HBV RNA, hepatitis B virus RNA; IU, international unit; LLOQ, lower limit of quantification; NA, nucleos(t)ide analogue

# AROHBV1001: Effect of JNJ-3989 and NA treatment on reduction in viral markers for individual patients (2/2)

Change in viral markers for individual patients from Day 0 to Day 168



HBcrAg, hepatitis B core related antigen; HBeAg, hepatitis B e-antigen; HBsAg, hepatitis B surface antigen; HBV RNA, hepatitis B virus RNA; IU, international units; NA, nucleos(t)ide analogue; PEIU, Paul Erlich Institute Units

# AROHBV1001: Conclusions

Treatment with JNJ-3989 (100–400mg, Q4W) in combination with NA resulted in **sustained reductions of all viral markers** HBsAg, HBeAg, HBcrAg and HBV RNA

Treatment with JNJ-3989 (100–400mg, Q4W) and an NA was associated with greater HBsAg reductions in:

- HBeAg-positive patients
- Patients with higher levels of HBV RNA, HBeAg and HBcrAg at baseline

Reductions in HBsAg and HBV RNA were more pronounced compared with HBeAg and HBcrAg

These findings are being evaluated in larger Phase 2b studies

# Acknowledgments

We express our gratitude to the patients who participated in this study. The authors also thank other Arrowhead staff members for their contributions to this study. This study was sponsored by Arrowhead Pharmaceuticals, Inc. Medical writing support for the development of this presentation, under the direction of the authors, was provided by Eleanor Coppins, of Ashfield MedComms, an Ashfield Health company, and funded by Janssen Pharmaceuticals.